ClinicalTrials.gg
Sign In

Leukemia, Megakaryoblastic, Acute clinical trials

The registry lists 172 studies for Leukemia, Megakaryoblastic, Acute across more than 10 countries. 0 are recruiting or about to start. 44 of them are mainly about Leukemia, Megakaryoblastic, Acute (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Status

Completed
126
Terminated
25
Status unknown
13
Withdrawn
4
Active, not recruiting
3
No longer available
1

Phase

Phase 2
80
Phase 1
56
Phase 3
23
Early Phase 1
1
Phase 4
1

Where

United States
134
Canada
10
Italy
10
United Kingdom
9
France
9
Belgium
8

Who runs them

National Cancer Institute (NCI) (42) · SWOG Cancer Research Network (11) · Fred Hutchinson Cancer Center (11) · Case Comprehensive Cancer Center (10) · Roswell Park Cancer Institute (8) · European Organisation for Research and Treatment of Cancer - EORTC (8) · Alliance for Clinical Trials in Oncology (6) · Eastern Cooperative Oncology Group (6)

What is being tested here

Drugs under test in Leukemia, Megakaryoblastic, Acute studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Cytarabine0342
Etoposide0214
Busulfan0113
Gemtuzumab0612
Idarubicin0112
Mitoxantrone0012
Tipifarnib0211
Fludarabine phosphate0011
Fludarabine0011
Daunorubicin0211

Drug classes tested here Antimetabolites 64 · Alkylating agents 18 · Calcineurin inhibitors 8 · HDAC inhibitors 7 · Proteasome inhibitors 6

Coming up

0phase 3 studies under way
1study finishes main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The study

Who these studies take

No Leukemia, Megakaryoblastic, Acute study is recruiting now.

Across all 172 studies, recruiting or not: 33% stop at 75 or younger and 21% at 65; 28% take children; 1% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Leukemia, Megakaryoblastic, Acute studies take

Of 10 phase 2 interventional studies under Leukemia, Megakaryoblastic, Acute, half reached primary completion within 60 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 260 mo50–118 · 10 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 172. Browse all 172 → or search them.